Gemcitabine
Gemcitabine (Gemzar, 2',2'-difluorodeoxycytidine) is a cytotoxic antimetabolite, a pyrimidine nucleoside analog of deoxycytidine given intravenously as a component of standard regimens for pancreatic ductal adenocarcinoma, biliary tract cancer and cholangiocarcinoma, urothelial carcinoma, non-small cell lung cancer and breast cancer.
Gemcitabine (Gemzar, 2',2'-difluorodeoxycytidine) is a cytotoxic antimetabolite, a pyrimidine nucleoside analog of deoxycytidine given intravenously as a component of standard regimens for pancreatic ductal adenocarcinoma, biliary tract cancer and cholangiocarcinoma, urothelial carcinoma, non-small cell lung cancer and breast cancer. It is a prodrug in effect: nucleoside transporters, principally hENT1, carry it into the cell, deoxycytidine kinase performs the rate-limiting first phosphorylation, and the resulting di- and triphosphates act through two complementary routes. The triphosphate competes with deoxycytidine triphosphate for incorporation into replicating DNA, where one further nucleotide is added before synthesis halts — a masked chain termination that repair exonucleases cannot easily excise — while the diphosphate inhibits ribonucleotide reductase and depletes deoxynucleotide pools. The second action reinforces the first, since falling dCTP both removes gemcitabine's competitor at the polymerase and relieves feedback inhibition on the kinase that activates it. Cytidine deaminase inactivates the drug, so the balance between activating kinase and deaminating enzyme, along with hENT1 abundance, largely sets how much active metabolite a tumor accumulates.
Its principal dose-limiting toxicity is myelosuppression; gastrointestinal effects are common but not generally dose-limiting, and because regimens such as gemcitabine plus cisplatin carry substantial emetic risk, antiemetic prophylaxis is routine. In practice gemcitabine is used more often as a backbone partner than alone — with cisplatin in biliary tract and urothelial cancer, with nab-paclitaxel in pancreatic cancer, and with checkpoint inhibitors such as durvalumab and pembrolizumab, reflecting the capacity of gemcitabine-induced immunogenic cell death to release damage-associated molecular patterns including HMGB1 and prime antitumor immunity within the tumor microenvironment.
It also serves as the comparator against which newer regimens are measured — enfortumab vedotin plus pembrolizumab in metastatic urothelial carcinoma, for instance — and as the reference cytotoxic in studies of alternatives such as FOLFIRINOX, which combines fluorouracil, oxaliplatin and irinotecan. Benefit is limited by intrinsic and acquired resistance, and current work addresses this through predictive biomarkers of response, dissection of resistance-associated signaling such as Phosphatidylinositol 3-kinase (PI3K)/Protein kinase B (PKB) and CD44/JAK2/STAT3 and DNA damage repair capacity, and nanomedicine delivery intended to concentrate drug at the tumor — a particular concern in pancreatic cancer, where dense stroma limits how much reaches the cells at all.
Where the papers sit
31 papers from the last 6 months study gemcitabine directly · updated from PubMed 12 Nov 2026
Study type 2 clinical trials · 9 observational · 2 human data · 16 preclinical · 2 unclassified
Themes 4 themes · 1 paradigm shift
-
Pancreatic Cancer Chemotherapy
Pancreatic cancer treatment is moving from standard chemotherapy alone toward biomarker-guided combinations, improved delivery and stromal remodeling. Gemcitabine is being paired with nab-paclitaxel, S-1, RNA interference or metabolic targeting of oxidative phosphorylation and pyrimidine synthesis. Nanocarriers and organoid or xenograft models aim to overcome poor tumor penetration and acquired resistance. Clinical studies continue to weigh these strategies against FOLFIRINOX and age- or nutrition-related treatment tolerance.
10 papers · 32.3%
-
Clinical Chemotherapy Combinations
Gemcitabine–cisplatin remains a clinical backbone in urothelial and biliary cancers, increasingly paired with immune checkpoint therapy or biomarker selection. Enfortumab vedotin plus pembrolizumab is challenging this backbone in metastatic urothelial carcinoma. Cholangiocarcinoma studies emphasize circulating tumor DNA, IDH1 status and DOT1L expression for treatment selection. Antiemetic optimization, regional delivery and controlled-release nanomedicines address toxicity and drug exposure.
7 papers · 22.6%
-
Gallbladder Cancer Treatment
Gallbladder cancer work links gemcitabine resistance to mitochondrial quality control and tests gemcitabine plus nab-paclitaxel as first-line therapy. SUMOylated Reptin, PINK1-driven mitophagy and reduced reactive oxygen species form the central resistance mechanism. The clinical study focuses on efficacy and safety in unresectable disease, while the mechanistic study points toward mitophagy-related biomarkers or targets. Evidence remains early, with no established way to translate this mechanism into treatment selection.
2 papers · 6.5%
-
Others — Cancer Drug Response
Cancer drug-response research spans immune activation, drug resistance, targeted delivery and biomarker discovery across several malignancies. Gemcitabine is being combined with checkpoint blockade, engineered immune therapies and antibody or small-molecule conjugates. Recurrent mechanisms include CD8+ T-cell expansion, lactylation, ENT1-mediated uptake, EMT-Notch signaling and DNA-repair regulation. The diseases and interventions vary too widely to establish one shared therapeutic direction.
12 papers · 38.7%
Gemcitabine is not only a direct cytotoxic drug but can actively reprogram antitumor immunity
The colorectal cancer cell-line and mouse-model study and the engineered-bacteria pancreatic-cancer mouse-model study assume gemcitabine primarily acts by killing tumor cells, but instead show that it can reshape the immune response: gemcitabine promoted lactylation, CD8+ T-cell infiltration, and inflammatory effector activity during anti-PD-L1 therapy in colorectal cancer, while in pancreatic cancer it synergized with indole-3-acetic acid to eliminate neutrophils, improve bacterial tumor colonization, and strengthen T-cell-mediated immunity. This shifts gemcitabine from being treated solely as a tumor-directed cytotoxic component to being considered an immune-modulating component whose therapeutic value can depend on remodeling the tumor microenvironment and coordinating immunotherapy or engineered biological therapy 42322856Jun 42810343Sep.
Papers
The 31 papers from the last 6 months that study gemcitabine directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Pancreatic Cancer Chemotherapy (10)
- Gemcitabine Delivery and Nucleolin-Targeting Nanocarriers Based on N6L-Functionalized Polyelectrolyte Complexes and Layer-By-Layer Lipid Nanoparticles. Biomacromolecules · 9 Nov 2026 PMID 43002045
- Exosome-Inspired Proteolipid Nanoparticles Enable Safe, Extrahepatic RNAi-Chemo Therapy Through Cholesterol-Free, Tumor-Preferential Delivery. Advanced healthcare materials · 27 Oct 2026 PMID 42935085
- Therapeutic Co-targeting of Oxidative Phosphorylation and Pyrimidine Synthesis Restores Gemcitabine Response in Pancreatic Ductal Adenocarcinoma. Translational research : the journal of laboratory and clinical medicine · 13 Sept 2026 PMID 42732873
- Neoadjuvant Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma: A Propensity Score-matched Study. Anticancer research · 31 Aug 2026 PMID 42674690
- Chemotherapy-induced CAF-associated stromal remodeling in a humanized stroma pancreatic ductal adenocarcinoma organoid xenograft model: a comparison between GP and GS. Human cell · 24 Aug 2026 PMID 42635882
- Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 27 Jul 2026 PMID 42507965
- Association Between Geriatric Nutritional Risk Index and Gemcitabine Plus Nab-Paclitaxel Continuation in Elderly Patients With Pancreatic Cancer. Anticancer research · 29 Jun 2026 PMID 42373239
- Breaking Through the Limits: Nanomedicine at the Service of New Drug Combinations to Tackle Pancreatic Cancer. Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 18 Jun 2026 PMID 42312894
- Effects of Chemotherapy on Survival Outcomes in Older Patients with Metastatic Pancreatic Cancer: A Nationwide Population-Based Study. Gut and liver · 10 Jun 2026 PMID 42270328
- Standardized workflow enables reproducibility of drug synergism detection: Results from a multi-center in vitro ring test on complex drug combinations in pancreatic cancer models. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 1 Jun 2026 PMID 42224741
Clinical Chemotherapy Combinations (7)
- Initial Clinical Experience With Gemcitabine, Cisplatin, and Nivolumab for Advanced Urothelial Carcinoma: A Four-case Series. In vivo (Athens, Greece) · 29 Oct 2026 PMID 42957262
- Real-world outcomes in circulating tumor DNA-detected isocitrate dehydrogenase 1-mutant cholangiocarcinoma: First-line gemcitabine and cisplatin with versus without immunotherapy. Cancer · 15 Oct 2026 PMID 42876026
- Gemcitabine release kinetics determines the anticancer and immunomodulatory activity of HPMA copolymer nanomedicines. Journal of controlled release : official journal of the Controlled Release Society · 23 Sept 2026 PMID 42777832
- Pharmacokinetic and pharmacodynamic sub-study of trans-arterial vs. intravenous gemcitabine in the TIGeR-PaC phase 3 clinical trial. Cancer chemotherapy and pharmacology · 16 Aug 2026 PMID 42604879
- First-Line Enfortumab Vedotin Plus Pembrolizumab vs Gemcitabine Plus Cisplatin for Metastatic Urothelial Carcinoma. JAMA network open · 1 Jul 2026 PMID 42384383
- Transcriptomic Profiling Identifies Higher DOT1L Expression as a Candidate Biomarker for a Positive Response to Gemcitabine in Cholangiocarcinoma. Cancer genomics & proteomics · 29 Jun 2026 PMID 42373229
- Antiemetic Efficacy of Aprepitant in Cisplatin-Gemcitabine Therapy for Biliary Tract Cancer: A Multicenter Study. Anticancer research · 27 May 2026 PMID 42203357
Gallbladder Cancer Treatment (2)
- SUMOylated Reptin maintains low intracellular ROS levels by activating mitophagy to drive gemcitabine resistance in gallbladder cancer. Cell death & disease · 9 Sept 2026 PMID 42716921
- Efficacy and Safety of First-Line Chemotherapy With Gemcitabine Plus Nab-Paclitaxel in Unresectable Gallbladder Cancer. Cancer medicine · 27 Aug 2026 PMID 42649595
Others — Cancer Drug Response (12)
- Reversal of the neutrophil barrier for potentiating immune-engineered bacteria therapy in pancreatic cancer. Cell reports. Medicine · 29 Sept 2026 PMID 42810343
- Fibroblast-associated TPM2 links cell-matrix remodeling to EMT-Notch signaling and gemcitabine resistance in intrahepatic cholangiocarcinoma. Cancer biology & therapy · 21 Sept 2026 PMID 42766730
- Enhancing gemcitabine uptake by promoting dimerization of ENT1 transporter improves response rates of patients with sarcoma. The Journal of clinical investigation · 3 Sept 2026 PMID 42691249
- Protracted Intraventricular Infusion of Gemcitabine to Circumvent the Blood Brain Barrier. Anticancer research · 31 Aug 2026 PMID 42674692
- Postoperative cutaneous metastasis of breast cancer with phenotypic conversion to triple-negative subtype: A case report. Medicine · 15 Aug 2026 PMID 42601691
- Design, Synthesis, and Biological Evaluation of a Cathepsin B-Activated Small Molecule-Drug Conjugate Targeting AKR1C3 to Enhance Chemotherapeutic Selectivity. Journal of medicinal chemistry · 18 Jul 2026 PMID 42470376
- Moonlighting role of meiotic SYCP1 in breast cancer: A chromatin-bound regulator of DNA repair, transcription, and drug resistance. Science advances · 8 Jul 2026 PMID 42418586
- Integrative multi-omics and machine learning reveal PLAUR as a Pan-Cancer prognostic biomarker and potential therapeutic target. Bioorganic chemistry · 2 Jul 2026 PMID 42391812
- Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy-Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones. Cancer research · 22 Jun 2026 PMID 42329854
- Gemcitabine enhanced the sensitivity of colorectal cancer to anti-PD-L1 therapy by promoting lactylation. International immunopharmacology · 20 Jun 2026 PMID 42322856
- Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO. Blood advances · 10 Jun 2026 PMID 42269085
- Spatiotemporally programmed nanomedicine engineering to resolve conflicting immunosignals in triple-negative breast cancer. Signal transduction and targeted therapy · 3 Jun 2026 PMID 42236688
By study type
Clinical trials (2)
- Pharmacokinetic and pharmacodynamic sub-study of trans-arterial vs. intravenous gemcitabine in the TIGeR-PaC phase 3 clinical trial. Cancer chemotherapy and pharmacology · 16 Aug 2026 PMID 42604879
- Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO. Blood advances · 10 Jun 2026 PMID 42269085
Observational studies and case reports (9)
- Initial Clinical Experience With Gemcitabine, Cisplatin, and Nivolumab for Advanced Urothelial Carcinoma: A Four-case Series. In vivo (Athens, Greece) · 29 Oct 2026 PMID 42957262
- Neoadjuvant Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma: A Propensity Score-matched Study. Anticancer research · 31 Aug 2026 PMID 42674690
- Efficacy and Safety of First-Line Chemotherapy With Gemcitabine Plus Nab-Paclitaxel in Unresectable Gallbladder Cancer. Cancer medicine · 27 Aug 2026 PMID 42649595
- Postoperative cutaneous metastasis of breast cancer with phenotypic conversion to triple-negative subtype: A case report. Medicine · 15 Aug 2026 PMID 42601691
- Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 27 Jul 2026 PMID 42507965
- First-Line Enfortumab Vedotin Plus Pembrolizumab vs Gemcitabine Plus Cisplatin for Metastatic Urothelial Carcinoma. JAMA network open · 1 Jul 2026 PMID 42384383
- Association Between Geriatric Nutritional Risk Index and Gemcitabine Plus Nab-Paclitaxel Continuation in Elderly Patients With Pancreatic Cancer. Anticancer research · 29 Jun 2026 PMID 42373239
- Effects of Chemotherapy on Survival Outcomes in Older Patients with Metastatic Pancreatic Cancer: A Nationwide Population-Based Study. Gut and liver · 10 Jun 2026 PMID 42270328
- Antiemetic Efficacy of Aprepitant in Cisplatin-Gemcitabine Therapy for Biliary Tract Cancer: A Multicenter Study. Anticancer research · 27 May 2026 PMID 42203357
Human data, design not indexed (2)
- Real-world outcomes in circulating tumor DNA-detected isocitrate dehydrogenase 1-mutant cholangiocarcinoma: First-line gemcitabine and cisplatin with versus without immunotherapy. Cancer · 15 Oct 2026 PMID 42876026
- Fibroblast-associated TPM2 links cell-matrix remodeling to EMT-Notch signaling and gemcitabine resistance in intrahepatic cholangiocarcinoma. Cancer biology & therapy · 21 Sept 2026 PMID 42766730
Preclinical: animal, cell and lab studies (16)
- Gemcitabine Delivery and Nucleolin-Targeting Nanocarriers Based on N6L-Functionalized Polyelectrolyte Complexes and Layer-By-Layer Lipid Nanoparticles. Biomacromolecules · 9 Nov 2026 PMID 43002045
- Reversal of the neutrophil barrier for potentiating immune-engineered bacteria therapy in pancreatic cancer. Cell reports. Medicine · 29 Sept 2026 PMID 42810343
- Gemcitabine release kinetics determines the anticancer and immunomodulatory activity of HPMA copolymer nanomedicines. Journal of controlled release : official journal of the Controlled Release Society · 23 Sept 2026 PMID 42777832
- SUMOylated Reptin maintains low intracellular ROS levels by activating mitophagy to drive gemcitabine resistance in gallbladder cancer. Cell death & disease · 9 Sept 2026 PMID 42716921
- Enhancing gemcitabine uptake by promoting dimerization of ENT1 transporter improves response rates of patients with sarcoma. The Journal of clinical investigation · 3 Sept 2026 PMID 42691249
- Protracted Intraventricular Infusion of Gemcitabine to Circumvent the Blood Brain Barrier. Anticancer research · 31 Aug 2026 PMID 42674692
- Chemotherapy-induced CAF-associated stromal remodeling in a humanized stroma pancreatic ductal adenocarcinoma organoid xenograft model: a comparison between GP and GS. Human cell · 24 Aug 2026 PMID 42635882
- Design, Synthesis, and Biological Evaluation of a Cathepsin B-Activated Small Molecule-Drug Conjugate Targeting AKR1C3 to Enhance Chemotherapeutic Selectivity. Journal of medicinal chemistry · 18 Jul 2026 PMID 42470376
- Moonlighting role of meiotic SYCP1 in breast cancer: A chromatin-bound regulator of DNA repair, transcription, and drug resistance. Science advances · 8 Jul 2026 PMID 42418586
- Integrative multi-omics and machine learning reveal PLAUR as a Pan-Cancer prognostic biomarker and potential therapeutic target. Bioorganic chemistry · 2 Jul 2026 PMID 42391812
- Transcriptomic Profiling Identifies Higher DOT1L Expression as a Candidate Biomarker for a Positive Response to Gemcitabine in Cholangiocarcinoma. Cancer genomics & proteomics · 29 Jun 2026 PMID 42373229
- Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy-Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones. Cancer research · 22 Jun 2026 PMID 42329854
- Gemcitabine enhanced the sensitivity of colorectal cancer to anti-PD-L1 therapy by promoting lactylation. International immunopharmacology · 20 Jun 2026 PMID 42322856
- Breaking Through the Limits: Nanomedicine at the Service of New Drug Combinations to Tackle Pancreatic Cancer. Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 18 Jun 2026 PMID 42312894
- Spatiotemporally programmed nanomedicine engineering to resolve conflicting immunosignals in triple-negative breast cancer. Signal transduction and targeted therapy · 3 Jun 2026 PMID 42236688
- Standardized workflow enables reproducibility of drug synergism detection: Results from a multi-center in vitro ring test on complex drug combinations in pancreatic cancer models. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 1 Jun 2026 PMID 42224741
Unclassified: not yet indexed with MeSH (2)
- Exosome-Inspired Proteolipid Nanoparticles Enable Safe, Extrahepatic RNAi-Chemo Therapy Through Cholesterol-Free, Tumor-Preferential Delivery. Advanced healthcare materials · 27 Oct 2026 PMID 42935085
- Therapeutic Co-targeting of Oxidative Phosphorylation and Pyrimidine Synthesis Restores Gemcitabine Response in Pancreatic Ductal Adenocarcinoma. Translational research : the journal of laboratory and clinical medicine · 13 Sept 2026 PMID 42732873
Written from 31 PubMed abstracts, each one listed by PMID above. Published: 2026-06-16. Last written: 2026-09-23 by GPT. Corrections: 2026-08-08 by GPT. Reviewed by a human editor on 2026-07-23. Drafted by language models from published abstracts; not medical advice.